- Trial phase
- Approved
- Time to market
- Already approved and marketed (FDA-approved since 2019)
- Why 3/10
- XYOSTED is an already-approved, commercial-stage drug with no pending PDUFA date or pivotal readout in the next ~12 months. It represents a small portion of Halozyme's overall revenue; the company's primary value driver is its ENHANZE drug-delivery platform royalties from partners. There is no hard, dated binary catalyst for this specific drug.
XYOSTED itself presents no near-term binary catalyst. For HALO investors, the focus should be on ENHANZE royalty revenue growth (driven by partners like argenx's VYVGART Hytrulo and J&J's DARZALEX FASPRO) and the Q3 2026 earnings report on November 5, 2026. The stock trades above its mean analyst target, suggesting limited near-term upside based on consensus estimates.
Price Chart
Executive Summary
XYOSTED (testosterone enanthate) is an FDA-approved, once-weekly subcutaneous auto-injector for testosterone replacement therapy in adult males with hypogonadism. It was originally developed and brought to market by Antares Pharma, which Halozyme Therapeutics acquired in 2022 for approximately $960 million. XYOSTED is a commercial-stage product with no pending regulatory catalysts. For Halozyme, it is a secondary asset behind the company's core ENHANZE drug-delivery technology platform, which generates the majority of value through royalty partnerships with large pharma (J&J, Roche, argenx, Takeda). As of late October 2026, HALO trades at ~$125.63 with a consensus Buy rating and mean price target of ~$109.
How It Works
XYOSTED is a once-weekly subcutaneous (under-the-skin) auto-injector that delivers testosterone enanthate, a replacement therapy for adult males whose bodies do not produce enough natural testosterone (hypogonadism). It replaces testosterone at normal levels to restore growth, development, and function of male sex organs and secondary sexual characteristics.
Trial Status
XYOSTED was FDA-approved in 2019 (originally by Antares Pharma). It is a commercially marketed product with no ongoing pivotal clinical trials for a new indication. Halozyme acquired XYOSTED through its $960M acquisition of Antares Pharma in 2022.
The Two-Sided Case
Upcoming Catalysts
- No upcoming FDA/Pivotal binary catalysts for XYOSTED specifically, it is a mature, approved product. Halozyme's key near-term catalyst is Q3 2026 earnings on November 5, 2026, which will include product revenue updates across the portfolio including XYOSTED.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Halozyme Therapeutics, Inc. PRESS-RELEASE HALO ·Originating report